Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been given a $15.00 price objective by research analysts at Royal Bank Of Canada in a research note issued to investors on Friday. The brokerage currently has a “sell” rating on the stock. Royal Bank Of Canada’s price target indicates a potential upside of 0.67% from the stock’s previous close.

Other analysts also recently issued research reports about the company. Vetr downgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $31.05 target price on the stock. in a research note on Thursday, June 22nd. Cantor Fitzgerald set a $31.00 target price on Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a research note on Thursday, June 22nd. BidaskClub downgraded Teva Pharmaceutical Industries Limited from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 16th. Barclays PLC set a $19.00 target price on Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a research note on Friday. Finally, Citigroup Inc. downgraded Teva Pharmaceutical Industries Limited from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $32.00 to $19.00 in a research note on Wednesday, August 16th. Five analysts have rated the stock with a sell rating, eighteen have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $27.56.

Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 14.90 on Friday. The stock’s market capitalization is $15.14 billion. The stock’s 50 day moving average price is $16.57 and its 200-day moving average price is $25.51. Teva Pharmaceutical Industries Limited has a 52-week low of $14.30 and a 52-week high of $44.42.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The company had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. During the same quarter in the previous year, the company earned $1.25 EPS. The firm’s quarterly revenue was up 12.9% compared to the same quarter last year. On average, equities analysts expect that Teva Pharmaceutical Industries Limited will post $4.25 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Given a $15.00 Price Target by Royal Bank Of Canada Analysts” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/10/21/teva-pharmaceutical-industries-limited-teva-given-a-15-00-price-target-by-royal-bank-of-canada-analysts.html.

Large investors have recently bought and sold shares of the stock. San Francisco Sentry Investment Group CA acquired a new stake in shares of Teva Pharmaceutical Industries Limited in the second quarter valued at approximately $106,000. Kistler Tiffany Companies LLC increased its holdings in shares of Teva Pharmaceutical Industries Limited by 74.7% in the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock valued at $122,000 after purchasing an additional 1,571 shares during the last quarter. FNY Managed Accounts LLC acquired a new stake in shares of Teva Pharmaceutical Industries Limited in the first quarter valued at approximately $123,000. Bronfman E.L. Rothschild L.P. increased its holdings in shares of Teva Pharmaceutical Industries Limited by 2.6% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock valued at $123,000 after purchasing an additional 94 shares during the last quarter. Finally, Sterling Investment Advisors Ltd. increased its holdings in shares of Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after purchasing an additional 100 shares during the last quarter. 56.76% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.